INC Research Strengthens Asia/Pacific Capabilities Through Two New Offices in Japan
Offices in Osaka and Shinagawa in Tokyo provide strong clinical development hub for customers in world’s second largest pharmaceutical market
INC Research LLC, a therapeutically focused global clinical research organization (CRO) with a Trusted Process® for delivering reliable results, today announced the establishment of INC Research Japan KK with the opening of new locations in Osaka and the Shinagawa ward in Tokyo. The new operations provide INC Research’s global drug development customers access to an increasingly significant market and further expand the Company’s presence in the Asia/Pacific region. INC Research now has 20 offices in key locations across the Asia/Pacific region in addition to Japan, including a presence in China, India, Australia, Singapore, Philippines, South Korea, Taiwan, Hong Kong, Malaysia, Thailand, Indonesia and New Zealand.
“There is a growing enthusiasm from both pharma and government sectors for Japan to be involved in both global and regional clinical trials,” said Garth Tierney , Executive Vice President, Asia/Pacific. “In response, INC Research is implementing a very considered approach to the market that will create greater confidence among our customers in conducting trials in Japan, as well as ultimately provide more direct influence on how trials are conducted. Our Japanese customers already have responded positively to our Trusted Process methodology as it fits well with their requirements for high quality and predictability. We are very enthusiastic about bringing the continued benefits of drug development in this country to our customers.”
Through INC Research’s unique approach to the Japan market, the two offices initially will feature a core group of highly qualified, English-speaking management, regulatory and therapeutic staff who will create a bridge between the Company’s Trusted Process methodology and the way clinical research has traditionally been conducted in Japan. The establishment of Japanese business operations builds on INC Research’s long-term experience in Japan where it has partnered with local CROs to conduct numerous trials across a variety of therapeutic areas.
The Osaka office is located at Level 19 Hilton Plaza West Office Tower, 2-2-2 UMEDA, Kita-ku, Osaka 530-0001 and the Tokyo office is located at Level 28 Shinagawa Intercity Tower A, 2-15-1 Konan Minato-ku, Tokyo 108-6028. Both locations are strategically placed to serve major drug development areas and are connected by the region’s bullet train.
INC Research has provided Phase I to IV clinical development services in the Asia/Pacific region for nearly 20 years , conducting more than a 1,000 studies across a broad range of therapeutic areas. For more information on INC Research's clinical trial services and experience in Japan, please call +81-6-6450 9360 or visit the website.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
